2024.10.20Vol.6 No.14 NMPA China NMPA: ICH E2B (R3) Regional CN-Item Tag partially updated. Appendix 4-Example Safety Report Elements (Japanese translated and original Chinese)
2024.09.16Vol.6 No.13 NMPA China NMPA/CDE (No. 5): FAQ on Expedited Reporting of Safety Data during Clinical Trials: Japanese Translation and Original Chinese Version Uploaded, uploaded into HiroPhrma [REFERENCE]
2024.09.10Vol.6 No.11 NMPA NMPA/CDE (No.4) : Evaluation and Risk Management Procedures for Drug Clinical Study (Trial) : Japanese Translation & original Chinese Version upload in HiroPharma [REFERENCE] Notification
2024.08.28Vol.6 No.10 NMPA NMPA/CDE (No.3) : New Drug Benefit-Risk Assessment Technical Guidance Principles>>: Japanese Translation & original Chinese Version upload in HIroPharma [REFERENCE] Notification
2024.08.21Vol.6 No.9 NMPA NMPA/CDE (No.1 No.2) : Guideline for the Handling of Safety Information in Clinical and Clinical Trials: Japanese Translation & original Chinese Version upload in HIroPharma [REFERENCE] Notification
2024.07.18Vol.6 No.5 NMPA NMPA: Notification of Guidelines for Reporting Safety Information on Cosmetics issued by the State Administration of China
2022.05.11Vol.3 No.12 NMPA New Consulting Services for Safety Reporting by the NMPA during Clinical Trials and Marketing in the Chinese Pharmaceutical Market
